国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

MicuRx 盟科醫(yī)藥  
MicuRx 致力于發(fā)現(xiàn)和開發(fā)治療由耐藥菌引起感染的新型抗生素。該公司將其美國(guó)研發(fā)團(tuán)隊(duì)的豐富經(jīng)驗(yàn)與中國(guó)高品質(zhì)、高經(jīng)濟(jì)效益的藥物研發(fā)優(yōu)勢(shì)相結(jié)合，逐漸建立起一個(gè)治療各類耐藥革蘭氏陽(yáng)性和陰性菌新藥的平臺(tái)。該公司在美國(guó)加州硅谷和中國(guó)張江設(shè)有研發(fā)實(shí)驗(yàn)室。MicuRx 在首輪風(fēng)險(xiǎn)融資中從 Morningside Group 和 Devon Park Bioventures  募集了1200萬(wàn)美元。

 
盟科醫(yī)藥技術(shù)（上海）有限公司成立于2007年7月,致力于開發(fā)擁有自主知識(shí)產(chǎn)權(quán)的新一代抗菌藥物，以解決日益嚴(yán)重的、由于耐藥菌引起的感染，并在未來實(shí)現(xiàn)其工業(yè)生產(chǎn)和商業(yè)化。
經(jīng)過三年多的高效運(yùn)轉(zhuǎn)，公司自主研發(fā)的第一個(gè)候選1.1類新藥MRX-I，其前期研究得到了國(guó)家“十一五重大新藥創(chuàng)制”的一定支持，現(xiàn)已完成了前期藥學(xué)，毒理和生產(chǎn)工藝的研究，于2009年在中國(guó)申報(bào)臨床試驗(yàn)（IND），并已取得中國(guó)食品藥品監(jiān)督管理局進(jìn)行臨床試驗(yàn)的批文，已經(jīng)進(jìn)入一期人體臨床試驗(yàn)。該1.1類新藥有望于2015年前后在中、美同時(shí)上市，預(yù)期全球市場(chǎng)可達(dá)十億美元。
   


MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Infections due to multi-drug resistant bacteria have become a major threat to public health. In particular, methicillin-resistant Staphylococcus aureus (MRSA) has quickly spread from the hospital setting into the community and vancomycin-resistant enterococci (VRE) now represents at least 30% of all hospital enterococci infections. Importantly, bacteria continue to evolve and new strains of bacteria are resistant to even the newest antibiotics.

Using its proprietary drug discovery platform, MicuRx has generated a broad pipeline of antimicrobial agents to treat Gram-positive, Gram-negative and fungal infections. MicuRx's lead drug candidate is MRX-I, a next-generation oxazolidinone antibiotic with a superior therapeutic window projected to offer significant clinical differences over existing drugs. MicuRx filed its first Investigational New Drug (IND) application in China and received "Special Review" status from the State Food and Drug Administration.

In addition to its internal pipeline, MicuRx and Pfizer have entered a collaboration agreement to discover and develop new therapeutic agents to treat drug-resistant tuberculosis. All collaboration research will be conducted at the ZhangJiang High-Tech Park in Shanghai, China.